Johnson & Johnson to acquire Israel's Omrix for $465 million

piggy submitted, created time 1 month 1 week (www.reuters.com)

Johnson & Johnson Inc will acquire Israel's Omrix Biopharmaceuticals Inc for $27 a share, or a total of $465 million, the Globes financial news website said on Monday.

Omrix, which makes biosurgical sealants for the prevention of bleeding, or homeostasis, in surgery, is a partner of Johnson & Johnson unit Ethicon.
Ethicon has exclusive sales and marketing rights to Omrix's biosurgical products in the United States and the European Union.

A team from Ethicon was in Israel at the end of last week reviewing the company, the Globes report said

1 comment | Blog It | Email It | Keywords: economics pharma big pharma Johnson and Johnson Omrix acquisition Johnson & Johnson